Conditions Treated
Explore prescription medication options, including semaglutide, tirzepatide, sermorelin, and NAD+.
Rx required. Medications are prescribed only when appropriate.
GLP-1, peptide, and coenzyme medications
GLP-1
GLP-1 medication for weight management support
Semaglutide belongs to a class of medications known as GLP-1 receptor agonists. This medication is commonly used with medical weight loss programs and may reduce appetite and curb cravings.
GIP / GLP-1
Dual GIP/GLP-1 medication for weight management support
Tirzepatide acts on both GIP and GLP-1 receptors. This medication is commonly used with medical weight loss programs and may reduce appetite and curb cravings.
Peptide • Available Now
Injectable peptide medication for wellness and vitality support
Sermorelin is a peptide option related to growth hormone-releasing hormone pathways. It is not a GLP-1 medication. When clinically appropriate, it may improve sleep, promote recovery, and improve body composition.
Coenzyme
NAD+ medication for energy and wellness support.
NAD+ is a coenzyme involved in cellular energy production. When clinically appropriate, it may support energy recovery and overall wellness.
Coming Soon
PeachScripts is preparing for potential future peptide options if and when FDA approval and other applicable regulatory requirements allow. These products are not currently available through PeachScripts, and final offerings may change.
Coming Soon
Often referred to as the “Wolverine Stack”
Planned injectable peptide combination. Additional details, including availability and clinical criteria, will be provided if and when this option becomes available.
Coming Soon
Future peptide option
Under consideration for future PeachScripts availability. Final formulation, prescribing criteria, and availability have not been announced.
Coming Soon
Future peptide option
Under consideration for future PeachScripts availability. Final formulation, prescribing criteria, and availability have not been announced.
Compare
| Medication | Category | Primary Focus | Potential Benefits |
|---|---|---|---|
| Semaglutide | GLP-1 | Weight management | May reduce appetite and curb cravings as part of a medical weight loss program |
| Tirzepatide | GIP/GLP-1 | Weight management | May reduce appetite and curb cravings as part of a medical weight loss program |
| Sermorelin | Peptide / GHRH analog | Wellness & vitality | May improve sleep, promote recovery, and improve body composition |
| NAD+ | Coenzyme | Energy and vitality | May support energy recovery and overall wellness. |
Mechanism
Semaglutide belongs to a class of medications known as GLP-1 receptor agonists. This medication is commonly used with medical weight loss programs and may reduce appetite and curb cravings.
Tirzepatide acts on both GIP and GLP-1 receptors. This medication is commonly used with medical weight loss programs and may reduce appetite and curb cravings.
Sermorelin is a peptide option related to growth hormone-releasing hormone pathways. It is not a GLP-1 medication. When clinically appropriate, it may improve sleep, promote recovery, and improve body composition.
NAD+ is a coenzyme involved in cellular energy production. When clinically appropriate, it may support energy recovery and overall wellness.
Next Step
Start with a PeachScripts visit. A licensed provider will review your information and determine what may be appropriate.
FAQ
Semaglutide is a GLP-1 receptor agonist. Tirzepatide acts on both GIP and GLP-1 receptors. Both are commonly associated with medical weight-management treatment, but they are different medications.
No. Sermorelin is not a GLP-1 medication. It is a peptide related to growth hormone-releasing hormone pathways.
Semaglutide, tirzepatide, sermorelin, and NAD+ are commonly offered as injectable medications.
You can share which medication options you are interested in. Final prescribing decisions depend on clinical appropriateness after a licensed provider reviews your information.
No. Compounded medications are not FDA-approved. FDA does not verify compounded drugs for safety, effectiveness, or quality before they are marketed.
Prescription required. Medication availability may vary. Compounded medications, when prescribed, are not FDA-approved. FDA has reported concerns involving compounded semaglutide and tirzepatide, including dosing errors and adverse event reports, so dosing should always follow prescription instructions.
Visits start at $49 $25 in October$49. A licensed provider will review your information and determine what may be appropriate.